Latest News

In the last 7 days
Arimoclomol failure leaves Biogen/Ionis exposed Evaluate Group14:38 7-May-21
ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab Scrip Pharma Intelligence00:39 7-May-21
An Alzheimer's med for $2,500? Watchdog blasts Biogen's aducanumab data, suggests low price FiercePharma16:51 6-May-21
Rocky Road for Biogen's Aducanamab Now Includes Pricing Hurdle BioSpace15:49 6-May-21
Pharmalittle: Biden supports WTO proposal on Covid-19 vaccine IP; Biogen Alzheimer’s drug is… STAT14:27 6-May-21
Drug pricing watchdog joins the chorus of critics on Biogen's aducanumab: What about charging $2,560 per year? ENDPOINTS13:25 6-May-21
Drug pricing watchdog says there’s ‘insufficient’ evidence that Biogen’s Alzheimer’s medicine… Boston Globe22:19 5-May-21
ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug BioPharma Dive22:17 5-May-21
Biogen’s Alzheimer’s drug may only be cost-effective at $2,500 a year STAT22:01 5-May-21
Gilead vs. Biogen: Which Biotech Stock is a Better Buy? Investing.com17:37 5-May-21
Affinivax Appoints Elizabeth Radcliffe as Chief Financial Officer Business Wire (Press Release)13:03 5-May-21
NICE expands access for SMA drug Spinraza PharmaTimes09:11 5-May-21
Faze Medicines Appoints Douglas Kerr, M.D., Ph.D., to its Board of Directors Business Wire (Press Release)12:02 4-May-21
Yes, Federal Investigations May Require Your Company to Comply With a Stockholder’s Books-and-Records Demands JD Supra19:16 3-May-21
Can Process Confer Structure to Distinguish the Art after Biogen v. EMD Serono? IPWatchdog.com14:32 3-May-21
FDA rejects Biogen's subcutaneous Tysabri in multiple sclerosis FiercePharma12:40 3-May-21
In the last month
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, … GlobeNewswire (Press Release)14:02 1-May-21
Biogen and Bio-Thera Solutions Announce Collaboration on Proposed Actemra® (Tocilizumab) Biosimilar JD Supra22:05 30-Apr-21
Biogen won’t explain why FDA slapped down their bid for new Tysabri formulation ENDPOINTS16:10 30-Apr-21
FDA Blocks Biogen's sBLA for MS Drug BioSpace16:07 29-Apr-21
Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous… GlobeNewswire (Press Release)23:23 28-Apr-21
Could unclogging the brain's drainage system improve the efficacy of Biogen's aducanumab in… FierceBiotech16:10 28-Apr-21
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental,… Biogen (Press Release)12:37 28-Apr-21
Access to ALS Drug Likely Too Late for Chief Advocate Medpage Today21:23 27-Apr-21
New Emails Show Fear, Confusion Around Biogen Superspreader Conference BioSpace19:08 27-Apr-21
Biogen to expand access to its ALS drug, but move may come too late for some patients STAT17:59 27-Apr-21
Biosimilars: Roche and Biogen talk competition, price, opportunities BioProcess Insider17:27 27-Apr-21
Under pressure, Biogen will allow some patients early access to experimental ALS drug BioPharma Dive17:17 27-Apr-21
Ceding to Pressure, Biogen Will Offer Early Access to Tofersen in July BioSpace16:55 27-Apr-21
Biogen CEO Vounatsos nabs $18M payday amid challenges from Tecfidera generics, pandemic FiercePharma16:47 27-Apr-21
Biogen to open compassionate use programme for ALS patients with ‘rapidly progressive disease’ PMLiVE15:49 27-Apr-21
Biogen, under increasing public pressure, to offer early access to experimental ALS med FierceBiotech15:47 27-Apr-21
Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market ENDPOINTS14:32 27-Apr-21
Biogen reverses course on compassionate use for ALS drug tofersen with plans to open program in July ENDPOINTS12:40 27-Apr-21
Biogen to Make Experimental ALS Drug Available to Dying Patients BNN Bloomberg22:35 26-Apr-21
Biogen Inc. Wins Some, Loses Some, in Delaware Chancery Court Corporate Records Suit JD Supra22:59 23-Apr-21
Alzheimer's Aducanumab Redosing Study Underway Medpage Today22:32 23-Apr-21
18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401)… Biogen (Press Release)17:09 23-Apr-21
To create value, pharma companies should prioritize innovation, not shareholders STAT16:41 23-Apr-21
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization… JCN Newswire04:02 23-Apr-21
Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance Scrip Pharma Intelligence20:20 22-Apr-21
Biogen Inc (BIIB) Q1 2021 Earnings Call Transcript Nasdaq19:56 22-Apr-21
Biogen talks up approval plans for controversial Alzheimer’s drug as it nears FDA decision MarketWatch17:40 22-Apr-21
As review of its Alzheimer's drug wraps up, Biogen prepares for an uncertain launch BioPharma Dive17:14 22-Apr-21
Biogen readies Alzheimer’s hopeful aducanumab for U.S. launch as stateside sales plummet FiercePharma16:46 22-Apr-21
Biogen’s Alzheimer’s Drug is in the Home Stretch, but Can it Win Approval? BioSpace15:25 22-Apr-21
Why Biogen's Better-Than-Expected Q1 Results Weren't Good Enough The Motley Fool15:18 22-Apr-21
Damn the critics, Biogen CEO Vounatsos orders full speed ahead on prepping a controversial aducanumab launch as FDA… ENDPOINTS14:30 22-Apr-21
Biogen Tops First-Quarter Expectations And Boosts Earnings Outlook Investors Business Daily13:55 22-Apr-21
Biogen's Earnings Beat Forecasts. The Stock Is Rising. Barron's Online13:20 22-Apr-21
Biogen's stock is up, though revenue fell 25% for the quarter MarketWatch12:54 22-Apr-21
Biogen Boosts FY21 Adj. EPS Outlook; Q1 Results Top Estimates - Quick Facts RTT News12:37 22-Apr-21
Biogen raises 2021 adj. EPS outlook to $17.50-$19.00 from $17.00-$18.50 MarketWatch12:23 22-Apr-21
Biogen Earnings, Revenue Beat in Q1 Investing.com12:18 22-Apr-21
Biogen reveals new data for MS therapies Tysabri and Vumerity PMLiVE12:16 22-Apr-21
Is Biogen a Buy, Sell, or Hold? Investing.com21:44 21-Apr-21
Does Biogen Stand A Chance Of Topping Bearish First-Quarter Views? Investors Business Daily19:28 21-Apr-21
Biogen’s Alzheimer’s hopeful aducanumab faces ‘less than a coin flip’s chance’ of FDA approval: … FiercePharma16:10 21-Apr-21
ALS 'Compassionate Use' Again Hits National Media Medpage Today23:22 20-Apr-21
Immunome Appoints Corleen Roche as Chief Financial Officer Business Wire (Press Release)13:06 20-Apr-21
A Tecfidera Comeback? Investors Await More On Patent Plans From Biogen Scrip Pharma Intelligence19:21 19-Apr-21
How Biogen Stock Could Rise 85%. Two Drugs Are Critical. Barron's Online15:07 19-Apr-21
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to… Biogen (Press Release)12:33 19-Apr-21
New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with… GlobeNewswire (Press Release)12:33 16-Apr-21
MHRA grants marketing authorisation for new formulation of Tysabri Pharmafile12:06 16-Apr-21
New subcutaneous formulation of Tysabri approved in UK PharmaTimes09:35 16-Apr-21
Sage Therapeutics and Biogen Announce SAGE-324 Reduced Tremor in Phase 2 KINETIC Study Trial Site News00:08 16-Apr-21
Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing… Biogen (Press Release)21:40 15-Apr-21
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for Nasdaq18:36 15-Apr-21
Investor Notches Partial Win In Del. Suit For Biogen Records Law36003:29 15-Apr-21
Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual… GlobeNewswire (Press Release)21:10 14-Apr-21
Eli Lilly seeds a well-connected China neuro startup with drugs aiming at where Biogen, Voyager missed ENDPOINTS12:01 14-Apr-21
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study Nasdaq23:41 13-Apr-21
News Roundup: Bio-Thera, Henlius Advance Biologics Development Center for Biosimilars13:03 13-Apr-21
Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen Barron's Online21:33 12-Apr-21
Biogen and Sage’s Movement Disorder Therapy Reduces Tremor Score in Study BioSpace19:36 12-Apr-21
Biogen gets EU approval for subcutaneous Tysabri FiercePharma17:24 12-Apr-21
Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug Investors Business Daily16:09 12-Apr-21
Sage’s technical tremor win fails to move Evaluate Group15:40 12-Apr-21
Gene therapies for neurodegenerative diseases: Pfizer, Novartis, Biogen and others seek more from FDA ENDPOINTS14:05 12-Apr-21
Sage touts first win in $3B Biogen pact, but safety profile, doubts over data cloud road ahead ENDPOINTS13:55 12-Apr-21
Sage, Biogen's tremor drug hits goal, but 38% of people drop out FierceBiotech13:50 12-Apr-21
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in… Business Wire (Press Release)12:01 12-Apr-21
Biogen Announces Two New Nominees for Election to Board of Directors Biogen (Press Release)21:32 9-Apr-21
Biogen and Bio-Thera enter licencing agreement for arthritis biosimilar Pharmaceutical Technology15:49 9-Apr-21
Biogen to Report First Quarter 2021 Financial Results April 22, 2021 Biogen (Press Release)12:42 9-Apr-21
EU nod for new formulation of Biogen's Tysabri PharmaTimes10:06 9-Apr-21
Biogen acquires rights for potential Actemra biosimilar; Royalty Pharma buys lumasiran royalty stream for up to $240M ENDPOINTS16:11 8-Apr-21

      
            
      
    view more headlines
   
      
      
      
7 May 14:38
   

Biogen

Latest News

Biotech News Top Stories

UK Top Stories

World Top Stories